Weekly Chemotherapy in Advanced Prostatic Cancer
Author Information
Author(s): G. Francini, R. Petrioli, A. Manganelli, M. Cintorino, S. Marsili, A. Aquino, S. Mondillo
Primary Institution: University of Siena, Italy
Hypothesis
A weekly regimen of epirubicin will have less cardiotoxicity and similar efficacy compared to doxorubicin in patients with advanced prostatic cancer who have relapsed after hormonal therapy.
Conclusion
Weekly epirubicin treatment in advanced prostatic cancer patients may provide rapid palliative results similar to doxorubicin but with fewer side effects.
Supporting Evidence
- Patients receiving epirubicin had a median survival of 12.5 months compared to 8.0 months for those receiving doxorubicin.
- Pain intensity and tumor markers significantly decreased in responders after treatment.
- Cardiac performance worsened in a higher percentage of patients receiving doxorubicin compared to those receiving epirubicin.
Takeaway
Doctors tested two types of chemotherapy for men with advanced prostate cancer that didn't respond to hormone treatment. They found that one type, epirubicin, worked just as well but caused fewer heart problems.
Methodology
This was a randomized phase II study comparing the effectiveness of epirubicin and doxorubicin in patients with advanced prostatic carcinoma who were refractory to hormonal therapy.
Potential Biases
Potential bias in patient selection and response evaluation due to the subjective nature of some assessments.
Limitations
The study had a limited sample size and was conducted on patients who had already undergone hormonal therapy, which may affect generalizability.
Participant Demographics
72 subjects with advanced prostatic adenocarcinoma (stage D2), median age 65 years.
Statistical Information
P-Value
0.042
Confidence Interval
95% confidence limit; 23% to 50%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website